when will tirzepatide be approved FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Exploring Tirzepatide: A Revolutionary Approach
Description
The most common adverse effects are gastrointestinal and include nausea, vomiting, diarrhea, constipation, and abdominal pain

Heartburn or acid reflux worsens in some people due to delayed gastric emptying

It copies the effects of two natural hormones that control appetite and digestion GLP-1 and GIP

You do not need a video appointment or phone call to get a prescription, which makes the process faster than many competitors but also raises questions about the depth of medical oversight

Other trials showed tirzepatide reduced HbA1c and outperformed weekly semaglutide in several measures

Our goal is to use the medication to restore metabolic health and then find a maintenance strategy. This might mean lowering the dose, spacing out injections, or, for some patients, transitioning to natural metabolic support once they have reached a healthy baseline
